--- title: "Stoke Therapeutics (STOK) news: offering" url: "https://aibio.space/companies/stoke-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "STOK offering news: Stoke Therapeutics files new $200,000,000 at-the-market stock program. Stoke Therapeutics, Inc. (NASDAQ: STOK), United States." --- STOK Stoke Therapeutics, Inc. NASDAQ · United States # Stoke Therapeutics (STOK) news STOK offering news Financings · 2026-08-03 ## [Stoke Therapeutics files new $200,000,000 at-the-market stock program](https://aibio.space/news/stoke-therapeutics-files-new-200-000-000-market-stock-program/) Stoke filed a $200,000,000 at-the-market supplement with Cantor Fitzgerald & Co. as sales agent, which can be paid up to 3.0% of gross proceeds. It replaces an earlier supplement under which the company sold about 4.7 million shares for net proceeds of $146.4 million. ## Latest Stoke Therapeutics news 1. 2026-03-18 Financings [Stoke Therapeutics files automatic shelf with $150,000,000 ATM prospectus](https://aibio.space/news/stoke-therapeutics-files-automatic-shelf-150-000-000-atm-prospectus/) Stoke's shelf includes a $150,000,000 at-the-market program with Cantor Fitzgerald, which can be paid up to 3.0% of gross proceeds in commissions. The stock's last reported sale price was $33.96 on March 16, 2026. ## Stoke Therapeutics at a glance - **Ticker**: STOK - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $292.8 million ### Related companies - [Wave Life Sciences](https://aibio.space/companies/wave-life-sciences/) NASDAQ: WVE - [Disc Medicine](https://aibio.space/companies/disc-medicine/) NASDAQ: IRON - [PureTech Health](https://aibio.space/companies/puretech-health/) LSE: PRTC - [GRI Bio](https://aibio.space/companies/gri-bio/) NASDAQ: GRI - [Contineum Therapeutics](https://aibio.space/companies/contineum-therapeutics/) NASDAQ: CTNM - [Kailera Therapeutics](https://aibio.space/companies/kailera-therapeutics/) NASDAQ: KLRA - [Nuvation Bio](https://aibio.space/companies/nuvation-bio/) NYSE: NUVB - [Climb Bio](https://aibio.space/companies/climb-bio/) NASDAQ: CLYM ### Also on NASDAQ - [Krystal Biotech](https://aibio.space/companies/krystal-biotech/) KRYS - [TransCode Therapeutics](https://aibio.space/companies/transcode-therapeutics/) RNAZ - [Quantum Cyber](https://aibio.space/companies/quantum-cyber-n-v/) QUCY - [Scribe Therapeutics](https://aibio.space/companies/scribe-therapeutics/) SCTX - [ProKidney](https://aibio.space/companies/prokidney/) PROK - [Enanta Pharmaceuticals](https://aibio.space/companies/enanta-pharmaceuticals/) ENTA ## Stoke Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$184.4 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/) | [$36.6 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/) | | Research and development | [$137.9 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/) | [$89.1 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/) | | Net income (loss) | [-$6.9 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/) | [-$89.0 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/) | | Cash from operations | [$45.6 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/) | [-$86.9 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/) | | Cash and equivalents | [$84.2 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330557/) | [$128.0 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/) | | Short-term investments | [$200.4 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330557/) | [$88.9 million](https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $110.0 million, plus short-term investments of $182.8 million, $292.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Stoke Therapeutics Has Stoke Therapeutics raised money recently? Our latest story on this, dated Aug 3, 2026: "Stoke Therapeutics files new $200,000,000 at-the-market stock program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/stoke-therapeutics-files-new-200-000-000-market-stock-program/). What is the ticker symbol of Stoke Therapeutics? Stoke Therapeutics, Inc. trades under the ticker STOK on NASDAQ. Where is Stoke Therapeutics listed? Stoke Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0GT; LS:A2PLTL; LSX:A2PLTL. What is the SEC CIK of Stoke Therapeutics? The SEC Central Index Key (CIK) for Stoke Therapeutics, Inc. is 1623526. Its filings are on SEC EDGAR. How many shares does Stoke Therapeutics have outstanding? 64,526,242 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-03. Which country or territory is Stoke Therapeutics listed under? Our directory records Stoke Therapeutics, Inc. under United States. What does Stoke Therapeutics do? Our directory classifies Stoke Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Stoke Therapeutics? The ISIN recorded for Stoke Therapeutics, Inc. is US86150R1077. Does aibio.space cover Stoke Therapeutics? aibio.space lists Stoke Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Stoke Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What was Stoke Therapeutics's revenue last year? $184.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Stoke Therapeutics profitable? Stoke Therapeutics, Inc. reported a net loss of $6.9 million for the fiscal year ended Dec 31, 2025, and generated $45.6 million of cash from operations, per its annual report to the SEC. How much does Stoke Therapeutics spend on research and development? $137.9 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Stoke Therapeutics have? $292.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Stoke Therapeutics (STOK) stock news? Our latest story on Stoke Therapeutics, dated Aug 3, 2026: "Stoke Therapeutics files new $200,000,000 at-the-market stock program". Stoke filed a $200,000,000 at-the-market supplement with Cantor Fitzgerald & Co. as sales agent, which can be paid up to 3.0% of gross proceeds. It replaces an earlier supplement under which the company sold about 4.7 million shares for net proceeds of $146.4 million. [Source](https://aibio.space/news/stoke-therapeutics-files-new-200-000-000-market-stock-program/). ## Investor discussion: Stoke Therapeutics Members talk about Stoke Therapeutics (STOK). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Stoke Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-03 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330792/d137193d424b5.htm) 2. 2026-03-27 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1623526/000119312526129168/d119051d8k.htm) 3. 2026-03-18 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1623526/000119312526113933/d122133ds3asr.htm) 4. 2025-07-09 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1623526/000119312525157072/d917728ds3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:STOK on TradingView](https://www.tradingview.com/symbols/NASDAQ-STOK/). ## SEC filings and registration - **SEC name**: Stoke Therapeutics, Inc. - **CIK**: 1623526 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: STOK (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 45 WIGGINS AVENUE, BEDFORD, MA, 01730 - **Phone**: 781-430-8200 - **Shares outstanding**: 64,526,242 as of 2026-07-30 (10-Q filed 2026-08-03) - **Former names**: ASOthera Pharmaceuticals, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1623526/000119312526402820/d136438d8k.htm) filed 2026-09-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330804/d135735d8k.htm) filed 2026-08-03 - [424B5](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330792/d137193d424b5.htm) filed 2026-08-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330557/stok-20260630.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/stok-20260803.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1623526/000119312526289409/d924679d8k.htm) filed 2026-06-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1623526/000119312526257394/d15052d8k.htm) filed 2026-06-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1623526/000119312526212020/stok-20260507.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001623526), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Stoke Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker STOK, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Stoke Therapeutics, Inc. - **Ticker**: STOK - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US86150R1077 - **Other listed symbols**: GETTEX:0GT; LS:A2PLTL; LSX:A2PLTL - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-STOK/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/stoke-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Stoke Therapeutics (STOK) news: offering", 2026-10-31, https://aibio.space/companies/stoke-therapeutics/